Medical Health & Life Science Research News

Research details developments in the biosimilars market worth 23.63 billion USD by 2023

Medical Market Research

MarketsandMarkets Logo (PRNewsfoto/MarketsandMarkets) PUNE, India, April 6, 2018 /PRNewswire/ -- According to a new market research report "Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 23.63 Billion by 2023 from USD 5.95 Billion in 2018, at a CAGR of 31.7%.

- Advertising -

Browse 176 market data Tables and 37 Figures spread through 181 Pages and in-depth TOC on "Biosimilars Market"

www.marketsandmarkets.com/Market-R…m_campaign=PaidPR

Early buyers will receive 10% customization on this report 

The factors expected to drive the growth of this market include the increasing demand for biosimilar drugs due to their cost-effectiveness and the rising incidence of chronic diseases.

Recombinant glycosylated proteins are expected to be accounted for the largest market share in 2018 

By product, the biosimilar market is classified into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Recombinant glycosylated proteins are expected to hold the largest share of the market during the forecast period.

The key factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins and presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products.

- Advertising -

Ask for PDF Brochure @ www.marketsandmarkets.com/pdfdownl…m_campaign=PaidPR

The in-house manufacturing segment held the largest share of the market in 2017 

By type of manufacturing, the market is segmented into in-house manufacturing and contract manufacturing. In-house manufacturing accounted for the largest share of the global Biosimilars Market in 2017.

The growing demand for cost-effective biosimilar products owing to the rising incidence of various diseases is driving the growth of the in-house manufacturing segment

Europe accounted for the largest share of the global Biosimilars Market in 2017 

Europe accounted for largest share of the global Biosimilars Market in 2017, followed by Asia. Growth in this regional market is expected to be driven by patent expiry of biologic products & the launch of new biosimilars, raising incidence of chronic disorders, and the emergence of new market participants

Key players in the Biosimilars Market include Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy's Laboratories (India), Celltrion (South Korea), and Samsung Biologics (South Korea).

Know more about the Biosimilars Market: 

www.marketsandmarkets.com/Market-R…m_campaign=PaidPR

News From

MarketsandMarkets™ - Business ResearchMarketsandMarkets™
Category: Market Research Publishers and RetailersCompany about: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...
This email address is being protected from spambots. You need JavaScript enabled to view it.